Biofrontera Inc. (BFRI) Statistics & Valuation Metrics

Total Valuation

Biofrontera has a market cap or net worth of $4.84 million. The enterprise value is $4.67 million.

Market Cap	4.84M
Enterprise Value	4.67M

Important Dates

The next estimated earnings date is Friday, August 9, 2024, before market open.

Earnings Date	Aug 9, 2024
Ex-Dividend Date	n/a

Share Statistics

Biofrontera has 5.09 million shares outstanding. The number of shares has increased by 171.44% in one year.

Shares Outstanding	5.09M
Shares Change (YoY)	+171.44%
Shares Change (QoQ)	+134.34%
Owned by Insiders (%)	28.29%
Owned by Institutions (%)	43.86%
Float	2.62M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.15
Forward PS	0.11
PB Ratio	n/a
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	0.14
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.44

Current Ratio	1.44
Quick Ratio	0.54
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-11.54

Financial Efficiency

Return on equity (ROE) is -1,217.20%.

Return on Equity (ROE)	-1,217.20%
Return on Assets (ROA)	-74.80%
Return on Capital (ROIC)	n/a
Revenue Per Employee	$400,627
Profits Per Employee	-$278,193
Employee Count	83
Asset Turnover	1.08
Inventory Turnover	2.50

Taxes

In the past 12 months, Biofrontera has paid $10,000 in taxes.

Income Tax	10,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -91.94% in the last 52 weeks. The beta is 0.46, so Biofrontera's price volatility has been lower than the market average.

Beta (1Y)	0.46
52-Week Price Change	-91.94%
50-Day Moving Average	1.34
200-Day Moving Average	2.98
Relative Strength Index (RSI)	39.43
Average Volume (20 Days)	26,885

Short Selling Information

The latest short interest is 15,401, so 0.30% of the outstanding shares have been sold short.

Income Statement

In the last 12 months, Biofrontera had revenue of $33.25 million and -$23.09 million in losses. Loss per share was -$10.20.

Revenue	33.25M
Gross Profit	16.29M
Operating Income	-22.35M
Pretax Income	-23.08M
Net Income	-23.09M
EBITDA	-20.14M
EBIT	-21.24M
Loss Per Share	-$10.20

Full Income Statement

Balance Sheet

The company has $3.84 million in cash and $3.67 million in debt, giving a net cash position of $174,000 or $0.03 per share.

Cash & Cash Equivalents	3.84M
Total Debt	3.67M
Net Cash	174,000
Net Cash Per Share	$0.03
Equity / Book Value	-5.42M
Book Value Per Share	-1.06
Working Capital	6.12M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$24.53 million and capital expenditures -$48,000, giving a free cash flow of -$24.58 million.

Operating Cash Flow	-24.53M
Capital Expenditures	-48,000
Free Cash Flow	-24.58M
FCF Per Share	-$6.78

Full Cash Flow Statement

Margins

Gross margin is 48.99%, with operating and profit margins of -67.22% and -69.44%.

Gross Margin	48.99%
Operating Margin	-67.22%
Pretax Margin	-69.41%
Profit Margin	-69.44%
EBITDA Margin	-60.55%
EBIT Margin	-63.88%
FCF Margin	-73.92%

Dividends & Yields

Biofrontera does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-171.44%
Shareholder Yield	-171.44%
Earnings Yield	-476.81%
FCF Yield	-507.56%

Analyst Forecast

The average price target for Biofrontera is $18.00, which is 1,791.75% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$18.00
Price Target Difference	1,791.75%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	25.98%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on July 5, 2023. It was a reverse split with a ratio of 1:20.

Last Split Date	Jul 5, 2023
Split Type	Reverse
Split Ratio	1:20

Scores

Biofrontera has an Altman Z-Score of -7.36 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-7.36
Piotroski F-Score	3

FAQs

Biofrontera Inc. (BFRI) Statistics & Valuation Metrics - Stock Analysis? ›

The highest analyst price target is $7.00 ,the lowest forecast is $7.00. The average price target represents 600.00% Increase from the current price of $1. Biofrontera's analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.

See Details ›

Is BFRI stock a good buy? ›

Show Me More ›

What is the stock forecast for BFRI in 2025? ›

On average, analysts forecast that BFRI's EPS will be -$0.23 for 2025, with the lowest EPS forecast at -$0.23, and the highest EPS forecast at -$0.23. In 2026, BFRI's EPS is forecast to hit $0.41 (min: $0.41, max: $0.41).

Learn More ›

What does Biofrontera do? ›

Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics.

Discover More ›

What is Bior stock forecast for 2025? ›

Biora Therapeutics, Inc. stock forecast for 2025: $ 0.312649 (-54.35%) Biora Therapeutics, Inc. stock prediction for 2030: $ 0.006197 (-99.10%)

Learn More ›

What is the stock price prediction for IMGN? ›

IMGN Stock 12 Month Forecast

Based on 9 Wall Street analysts offering 12 month price targets for ImmunoGen in the last 3 months. The average price target is $31.10 with a high forecast of $31.26 and a low forecast of $31.00. The average price target represents a -0.42% change from the last price of $31.23.

Explore More ›

What is the target price for MPWR? ›

The average price target for Monolithic Power is $810.80. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $900.00 ,the lowest forecast is $740.00. The average price target represents -4.90% Decrease from the current price of $852.56.

Tell Me More ›

What is the stock price forecast for Gehc in 2025? ›

According to analysts, GEHC price target is 93.10 USD with a max estimate of 105.00 USD and a min estimate of 86.00 USD.

Get More Info Here ›

What is the price prediction for Parker stock? ›

Stock Price Forecast

The 16 analysts with 12-month price forecasts for Parker-Hannifin stock have an average target of 562.81, with a low estimate of 425 and a high estimate of 650.

Tell Me More ›

What is pin stock price prediction? ›

According to analysts, PINS price target is 46.16 USD with a max estimate of 52.00 USD and a min estimate of 34.00 USD. Check if this forecast comes true in a year, meanwhile watch Pinterest, Inc. stock price chart and keep track of the current situation with PINS news and stock market news.

View Details ›

What is the highest valued single stock? ›

Berkshire Hathaway is the most expensive stock listed on U.S. exchanges.

What is a good number of shares to hold? ›

Most experts tell beginners that if you're going to invest in individual stocks, you should ultimately try to have at least 10 to 15 different stocks in your portfolio to properly diversify your holdings.

Know More ›

Will Foot Locker stock go up? ›

The average price target for Foot Locker is $27.25. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $35.00 ,the lowest forecast is $17.00. The average price target represents 13.02% Increase from the current price of $24.11.

Short Interest	15,401
Short Previous Month	7,916
Short % of Shares Out	0.30%
Short % of Float	0.59%
Short Ratio (days to cover)	0.10

Biofrontera Inc. (BFRI) Statistics & Valuation Metrics - Stock Analysis (2024)